ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013

DeVita: No Decision Yet On FCRF Award

July 17, 1987

NCAB Puts 20% Cap On P01 Budget Raises To Stem Requests Exceeding NCI’s.

February 25, 2000

NCI Issues 8 Awards, 12 Feasibility Grants, In New SPORE Program

October 9, 1992

In Brief: George Vande Woude To Wistar institute Board; Donald Pinkel To Head Pediatric Leukemia Program

October 18, 1985

NAS Report Advises Candidates on Filling Key Science Positions.

October 31, 2008